Company research
Scholar Rock Holding Corp
CIK 1727196Updated Sep 26, 2026
SecuritySRRK · NASDAQ · equity
SRRK price & chart
Loading TradingView…
NASDAQ:SRRK on TradingView ↗About the company
Scholar Rock is delivering muscle-targeted breakthroughs to transform the treatment of spinal muscular atrophy (SMA) and other rare neuromuscular diseases where muscle atrophy remains a critical unmet need. Scholar Rock intends to commercialize ISEMBYLD (apitegromab-mstn) globally, beginning in the U.S. for individuals living with SMA who are 2 years of age and older and currently receiving a survival motor neuron 2 (SMN2)-targeted treatment.
In the news
Recent filings
4 filing
Regulation FD Disclosure
Items 7.01
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
SCHEDULE 13G/A filing
Other Events
Items 8.01, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 404,272,000Source | 474,922,000Source | 311,035,000Source | 358,168,000Source |
| Property, Plant and Equipment, NetUSD | 1,705,000Source | 2,761,000Source | 4,600,000Source | 7,384,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 323,527,000Source | 177,878,000Source | 101,855,000Source | 103,275,000Source |
| Assets, CurrentUSD | 385,147,000Source | 451,165,000Source | 288,194,000Source | 328,024,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 17,584,000Source | 13,887,000Source | 8,256,000Source | 12,663,000Source |
| Operating Lease, Right-of-Use AssetUSD | 10,382,000Source | 15,644,000Source | 11,417,000Source | 18,543,000Source |
| Other Assets, NoncurrentUSD | 3,231,000Source | 2,945,000Source | 4,417,000Source | 1,719,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 158,784,000Source | 106,288,000Source | 85,817,000Source | 97,933,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 108,000Source | 94,000Source | 76,000Source | 52,000Source |
| Additional Paid in CapitalUSD | 1,545,940,000Source | 1,291,095,000Source | 901,471,000Source | 771,699,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,300,654,000Source | -922,715,000Source | -676,421,000Source | -510,632,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 94,000Source | 160,000Source | 92,000Source | -884,000Source |
| Stockholders' Equity Attributable to ParentUSD | 245,488,000Source | 368,634,000Source | 225,218,000Source | 260,235,000Source |
| Liabilities and EquityUSD | 404,272,000Source | 474,922,000Source | 311,035,000Source | 358,168,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 55,419,000Source | 46,936,000Source | 32,741,000Source | 36,389,000Source |
| Operating Lease, Liability, CurrentUSD | 5,550,000Source | 5,774,000Source | 7,408,000Source | 7,852,000Source |
| Accounts Payable, CurrentUSD | 10,303,000Source | 10,095,000Source | 3,465,000Source | 3,994,000Source |
| Operating Lease, Liability, NoncurrentUSD | 3,656,000Source | 9,206,000Source | 4,392,000Source | 11,800,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 39,566,000Source | 31,067,000Source | 20,449,000Source | 24,321,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 99,709,000Source | 50,146,000Source | 48,684,000Source | 49,744,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -377,939,000Source | -246,294,000Source | -165,789,000Source | -134,502,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 75,600,000Source | 36,628,000Source | 27,142,000Source | 27,701,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | 208,000Source | 6,630,000Source | -529,000Source | -251,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -300,035,000Source | -200,949,000Source | -145,226,000Source | -132,694,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 218,687,000Source | -76,056,000Source | 41,141,000Source | -171,698,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 602,000Source | 98,000Source | 71,000Source | 1,064,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 228,399,000Source | 353,028,000Source | 102,574,000Source | 194,832,000Source |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | — | — | 3,000Source | — |
| Repayments of Long-term DebtUSD | 25,520,000Source | — | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | 76,023,000Source | -1,511,000Source | -109,560,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 327,334,000Source | 180,285,000Source | 104,262,000Source | 105,773,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 6,066,000Source | 6,617,000Source | 6,399,000Source | 4,372,000Source |
| Income Taxes Paid, NetUSD | 46,000Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | -2,000Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 75,600,000Source | 36,628,000Source | 27,142,000Source | 27,701,000Source |
| Amortization of Debt Issuance CostsUSD | 423,000Source | 253,000Source | 274,000Source | 720,000Source |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | — | — | -11,000Source | -33,000Source |
| General and Administrative ExpenseUSD | 176,205,000Source | 67,504,000Source | 49,395,000Source | 43,119,000Source |
| InterestExpenseNonoperatingUSD | 6,893,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -377,939,000Source | -246,294,000Source | -165,789,000Source | -134,502,000Source |
| Nonoperating Income (Expense)USD | 6,706,000Source | 5,760,000Source | 5,506,000Source | -132,000Source |
| Operating ExpensesUSD | 384,645,000Source | 252,054,000Source | 171,295,000Source | 167,563,000Source |
| Operating Lease, ExpenseUSD | — | 7,000,000Source | 8,300,000Source | 8,700,000Source |
| Other Nonoperating Income (Expense)USD | -301,000Source | — | — | — |
| Proceeds from Issuance of Common StockUSD | 91,660,000Source | 324,414,000Source | 97,709,000Source | 195,315,000Source |
| Proceeds from Issuance of Long-term DebtUSD | 24,668,000Source | — | — | — |
| Proceeds from Stock Options ExercisedUSD | 23,811,000Source | 19,114,000Source | 1,399,000Source | 492,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 0Source | — | — | 33,193,000Source |
| Operating Income (Loss)USD | -384,645,000Source | -252,054,000Source | -171,295,000Source | -134,370,000Source |
| Other Nonoperating Income (Expense)USD | -301,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -377,939,000Source | -246,294,000Source | -165,789,000Source | -134,502,000Source |
| Earnings Per Share, BasicUSD per share | -3.29Source | -2.47Source | -1.99Source | -2.26Source |
| Earnings Per Share, DilutedUSD per share | -3.29Source | -2.47Source | -1.99Source | -2.26Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 114,701,154Source | 99,838,102Source | 83,347,086Source | 59,611,656Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 114,701,154Source | 99,838,102Source | 83,347,086Source | 59,611,656Source |
| Interest Expense (non-operating)USD | 6,893,000Source | — | — | — |
| Additional Financial Items | ||||
| Depreciation, Depletion and Amortization, NonproductionUSD | 1,658,000Source | 1,937,000Source | 2,844,000Source | 2,986,000Source |
| General and Administrative ExpenseUSD | 176,205,000Source | 67,504,000Source | 49,395,000Source | 43,119,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -377,734,000Source | — | — | — |
| Interest Expense, DebtUSD | 6,300,000Source | 6,600,000Source | 6,500,000Source | 4,700,000Source |
| Nonoperating Income (Expense)USD | 6,706,000Source | 5,760,000Source | 5,506,000Source | -132,000Source |
| Operating ExpensesUSD | 384,645,000Source | 252,054,000Source | 171,295,000Source | 167,563,000Source |
| Operating Lease, ExpenseUSD | — | 7,000,000Source | 8,300,000Source | 8,700,000Source |
| Research and Development ExpenseUSD | 208,440,000Source | 184,550,000Source | 121,900,000Source | 124,444,000Source |
Filing attachments
tm2625362d1_ex99-1.htm · 8-K · 2026-09-14
EX-99.1 2 tm2625362d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA) September 11, 2026 ISEMBYLD is approved for use in all adults and children ≥2 years of age with SMA who are currently receiving a survival motor neuron 2 (SMN2)-targeted treatment ISEMBYLD recommended dose of 10 mg/kg showed a robust, clinically me…
Read attachment ↗tm2625362d1_ex99-2.htm · 8-K · 2026-09-14
EX-99.2 3 tm2625362d1_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 ISEMBYLD (apitegromab-mstn) FDA Approval Conference Call September 14, 2026 © 2026 Scholar Rock, Inc. All rights reserved. ────────────────────────────────────────────────── 2 Forward-Looking Statements Various statements in this presentation concerning the future expectations, plans and prospects of Scholar Rock Holding Corporation and Scholar Rock, Inc. (collectively, “Scholar Rock”), including without limita…
Read attachment ↗srrk-ex99_1.htm · 8-K · 2026-08-06
EX-99.1 2 srrk-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights • Apitegromab Biologics License Application (BLA) for spinal muscular atrophy (SMA) review by FDA continues to advance with two fill-finish facilities, representing two independent paths to an FDA approval decision by September 30, 2026 Prescription Drug User Fee Act (PDUFA) date • FDA review of second fill-finish facility progressing; Data pack…
Read attachment ↗srrk-20260507xex99d1.htm · 8-K · 2026-05-07
EX-99.1 2 srrk-20260507xex99d1.htm EX-99.1 Exhibit 99.1 Exhibit 99.1 Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights • FDA accepted apitegromab Biologics License Application (BLA) for treatment of children and adults with spinal muscular atrophy (SMA) with September 30, 2026 Prescription Drug User Fee Act (PDUFA) action date • Accepted apitegromab BLA includes two fill-finish facilities, Catalent Indiana LLC (part of Novo Nordisk), and …
Read attachment ↗srrk-20260507xex99d2.htm · 8-K · 2026-05-07
EX-99.2 3 srrk-20260507xex99d2.htm EX-99.2 Exhibit 99.2 © 2026 Scholar Rock, Inc. All rights reserved. Q1 2026 Earnings Call MAY 7, 2026 Exhibit 99.2 © 2026 Scholar Rock, Inc. All rights reserved. 2 TOPIC SPEAKER BUSINESS UPDATE David L. Hallal Chairman & Chief Executive Officer R&D PROGRESS Akshay Vaishnaw, M.D., Ph. D. President of R&D COMMERCIAL READINESS Keith Woods Chief Operating Officer COMPANY FINANCIALS Vikas Sinha Chief Financial Officer 5 Q&A SESS…
Read attachment ↗tm2610664d1_ex99-1.htm · 8-K · 2026-03-31
EX-99.1 2 tm2610664d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Scholar Rock Resubmits Biologics License Application (BLA) to FDA for Apitegromab for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA) Apitegromab BLA resubmission includes Catalent Indiana LLC (part of Novo Nordisk) and second U.S.-based fill-finish facility, aligned with FDA guidance from March 3, 2026 Type C meeting ──────────────────────────────────────────────────────────────────────────────────────────…
Read attachment ↗